Adastra Pharmaceuticals Inc. is a private clinical-stage oncology company committed to providing responsible solutions to advance patient care in oncology. The Adastra lead clinical candidate, zotiraciclib, is initially being developed for the treatment of glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG), two brain cancers characterized by Myc overexpression. Zotiraciclib is the subject of separate clinical studies in GBM, as well as an upcoming pilot study in DIPG.
